Related Experiment Video
Updated: Feb 22, 2026
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers
Diána Brauswetter1, Bianka Gurbi1, Attila Varga1
1MTA-SE Pathobiochemistry Research Group, Budapest, Hungary.
Abstract:
Pancreatic cancer is an increasing cause of cancer related death worldwide. KRAS is the dominant oncogene in this cancer type and molecular rationale would indicate, that inhibitors of the downstream target MEK could be appropriate targeted agents, but clinical trials have failed so far to achieve statistically significant benefit in unselected patients. We aimed to identify predictive molecular biomarkers that can help to define subgroups where MEK inhibitors might be beneficial alone or in combination. Next-generation sequencing data of 50 genes in three pancreatic cancer cell lines (MiaPaCa2, BxPC3 and Panc1) were analyzed and compared to the molecular profile of 138 clinical pancreatic cancer samples to identify the molecular subtypes of pancreatic cancer these cell lines represent. Luminescent cell viability assay was used to determine the sensitivity of cell lines to kinase inhibitors. Western blot was used to analyze the pathway activity of the examined cell lines. According to our cell viability and pathway activity data on these model cell lines only cells harboring the rare G12C KRAS mutation and low EGFR expression are sensitive to single MEK inhibitor (trametinib) treatment. The common G12D KRAS mutation leads to elevated baseline Akt activity, thus treatment with single MEK inhibitors fails. However, combination of MEK and Akt inhibitors are synergistic in this case. In case of wild-type KRAS and high EGFR expression MEK inhibitor induced Akt phosphorylation leads to trametinib resistance which necessitates for MEK and EGFR or Akt inhibitor combination treatment. In all we provide strong preclinical rational and possible molecular mechanism to revisit MEK inhibitor therapy in pancreatic cancer in both monotherapy and combination, based on molecular profile analysis of pancreatic cancer samples and cell lines. According to our most remarkable finding, a small subgroup of patients with G12C KRAS mutation may still benefit from MEK inhibitor monotherapy.
Insights
Pancreatic cancer patients with rare KRAS G12C mutations may benefit from MEK inhibitor monotherapy. Other KRAS mutations require combination therapies targeting MEK, EGFR, or Akt pathways for efficacy.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- Pancreatic cancer is a leading cause of cancer mortality globally.
- KRAS is a key oncogene in pancreatic cancer, but MEK inhibitors have shown limited success in unselected patients.
- Identifying predictive biomarkers is crucial for effective targeted therapy.
Purpose of the Study:
- To identify predictive molecular biomarkers for MEK inhibitor efficacy in pancreatic cancer.
- To define patient subgroups that may benefit from MEK inhibitors alone or in combination.
- To elucidate molecular mechanisms underlying MEK inhibitor response and resistance.
Main Methods:
- Analysis of next-generation sequencing data from pancreatic cancer cell lines and clinical samples.
- Cell viability assays to assess sensitivity to kinase inhibitors.
- Western blot analysis to evaluate pathway activity.
Main Results:
- Pancreatic cancer cell lines with KRAS G12C mutations and low EGFR expression responded to single-agent MEK inhibitor (trametinib) treatment.
- Cell lines with KRAS G12D mutations showed resistance to single MEK inhibitors due to elevated Akt activity, but responded synergistically to MEK and Akt inhibitor combinations.
- Wild-type KRAS with high EGFR expression developed resistance to MEK inhibitors, necessitating combination therapy with EGFR or Akt inhibitors.
Conclusions:
- MEK inhibitor therapy can be revisited in pancreatic cancer based on specific molecular profiles.
- A subset of patients with KRAS G12C mutations may benefit from MEK inhibitor monotherapy.
- Combination strategies involving MEK, EGFR, and Akt inhibitors show promise for other molecular subtypes.
